Amyloidosis: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

No stopped trial with a stated reason in this view.

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

  2024-518343-38-00· Alnylam Pharmaceuticals Inc.· Source

• A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

  NCT07224672· GlaxoSmithKline· Source

• A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

  NCT05250973· Janssen Research & Development, LLC· Source

• Southeastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry

  NCT05974644· Virginia Commonwealth University· Source

• A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

  NCT05652335· Janssen Research & Development, LLC· Source

• HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT04153149· Alnylam Pharmaceuticals· Source

• PET/CT Imaging in Carriers of TTR Mutations

  NCT07591038· University of Texas Southwestern Medical Center· Source

• Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis

  NCT07901725· Regeneron Pharmaceuticals· Source

• Prevalence of Amyloidosis in Trauma Patients

  NCT06527521· Consorci Sanitari de l'Alt Penedès i Garraf· Source

• Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

  NCT06183931· Alexion Pharmaceuticals, Inc.· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 1
• Mendelian Randomization Analysis 1
• CRISPR-Cas Systems 3
• Gene Expression Profiling 3
• Sequence Analysis, RNA 3
• Exome Sequencing 3
• Proteomics 20
• Metabolomics 2
• Mass Spectrometry 14
• Flow Cytometry 1
• Immunohistochemistry 14
• Positron-Emission Tomography 32
• Magnetic Resonance Imaging 94
• Machine Learning 13
• Deep Learning 4
• Cohort Studies 41
• Genome-Wide Association Study 2

• Machine Learning-Driven Risk Prediction Model in Transthyretin Amyloid Cardiomyopathy.

  JAMA Cardiol, Oct 2026

• The role of "red flags" in the diagnostic work-up of hereditary transthyretin amyloidosis: a study using a machine-learning approach.

  Neurol Sci, Aug 2026

• AI-assisted diagnosis of cardiac amyloidosis using electrocardiograms and echocardiography: a multicenter retrospective study in China.

  BMC Med, Jun 2026

• Clinical and pathologic correlations of machine learning quantification of Aβ deposits across 3 brain regions of decedents with Alzheimer disease.

  J Neuropathol Exp Neurol, Jun 2026

• Amyloidosis secondary to familial Mediterranean fever: machine learning-based prediction models.

  Rheumatology (Oxford), May 2026

• Transferability of a US claims-based machine learning model for ATTRwt-CM identification: a retrospective evaluation in a German setting.

  Sci Rep, Apr 2026

• Predicting future cognitive impairment in preclinical Alzheimer's disease using amyloid PET and MRI: A multisite machine learning study.

  Neurobiol Aging, Apr 2026

• Machine learning for site risk prediction in clinical trials: development, external validation, and operational application in site qualification.

  Int J Med Inform, Feb 2026

• Unlocking the potential of nailfold videocapillaroscopy in diagnosing and staging wild-type transthyretin amyloidosis: A preliminary approach.

  Med Clin (Barc), Jan 2026

• A machine learning protocol for predicting structural distributions of amyloid-forming proteins from 2D IR spectra.

  Proc Natl Acad Sci U S A, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.